Ubrogepant prevents headache when administered in prodromal phase

A study presented at the European Headache Federation found that treatment with 100 mg of ubrogepant in the prodromal phase of a migraine attack prevented the development of headaches within 24 hours post-dose. The study examined the safety and efficacy of ubrogepant in 480 individuals and found that 45.5% of ubrogepant-treated prodrome events achieved a reduction in moderate-to-severe intensity headache within 24 hours compared to 28.6% of placebo-treated events. Additionally, absence of headache of any intensity within 24 hours was significant with ubrogepant compared to placebo. The study was conducted by Peter J. Goadsby, MD, PhD, FRS, and colleagues. Goadsby reports receiving grants and personal fees from various pharmaceutical companies.

Source link

error: Content is protected !!